Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients

Transplantation

Volumn 90, Issue 11, 2010, Pages 1204-1209

  Berenguer, Marina ^a,b   Aguilera, Victoria ^a   San Juan, Fernando ^a   Benlloch, Salvador ^a   Rubin, Angel ^a   López Andujar, Rafael ^a   Moya, Angel ^a   Pareja, Eugenia ^a   Montalva, Eva ^a   Yago, Maria ^a   De Juan, Manuel ^a   Mir, José ^a   Prieto, Martín ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cyclosporine; Hepatitis C recurrence; Immunosuppressant therapy; Liver transplantation; Steroids; Tacrolimus

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN A; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER GRAFT REJECTION; A; LIVER HISTOLOGY; LIVER SURGERY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; CALCINEURIN; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SPAIN; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650307419     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fa93fa     Document Type: Article

References (24)

1. Berenguer M. What determines the natural history of recurrent hepatitis C? J Hepatol 2005; 42: 448.
2. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127.
3. Berenguer M, Royuela A, Zamora J. Immunosuppression with cal-cineurin inhibitors in regards to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis. Liver Transpl 2007; 13: 21.
4. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63.
5. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717.
6. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepa-tology 2003; 38: 1282.
7. Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant patients. Liver Transpl 2006; 12: 762.
8. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease inpatient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
9. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: A prospective randomized trial. Liver Transpl 2004; 10: 1258.
10. Levy G, Villamil F, Samuel D, et al. Results of list2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation Transplantation 2004 77 1632.
11. O'Grady JG, Hardy P, Burroughs AK, et al.; UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: Poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137.
12. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N EnglJ Med1996; 334: 815.
13. Prieto M, Berenguer M, Rayón M, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250.
14. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240.
15. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492.
16. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
17. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125.
18. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. GUT 2002; 50: 697.
19. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226.
20. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975.
21. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738.
22. Silva M, Moya A, Berenguer M, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449.
23. Samonakis DN, Triantos CK, Thalheimer U,et al. Immunosuppression and donor age with respect to severity of HCv recurrence after liver transplantation. Liver Transpl 2005; 11: 386.
24. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884.